OncoMed Pharmaceuticals, Inc. , a clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor-initiating cells, announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's " PINNACLE " clinical trial of its anti-Notch2/3 cancer stem cell antibody, tarextumab , for the treatment of small cell lung cancer . Tarextumab is being studied in combination with chemotherapy in patients with previously untreated, extensive stage SCLC.
http://ift.tt/12fMLkz
http://ift.tt/12fMLkz
No comments:
Post a Comment